Lifitegrast, sold under the brand name Xiidra (/ˈzaɪdrə/), is a medication for the treatment of signs and symptoms of dry eye, a syndrome called keratoconjunctivitis sicca. Lifitegrast reduces inflammation by inhibiting inflammatory cell binding. It is often used in conjunction with ciclosporin (Ikervis or Restasis) for dry eye treatment including meibomian gland dysfunction and inflammatory dry eye.